

AMYOTROPHIC LATERAL SCLEROSIS RESEARCH PROGRAM



FY24
Appropriation
\$40M

IMPROVE TREATMENTS AND FIND CURES FOR PEOPLE WITH ALS

MISSION: Fund impactful research to develop ALS treatments

Program Priorities



Preclinical Treatment Discovery



Preclinical Treatment Validation




Clinical Outcomes and Biomarkers



Early Phase Clinical Trials

Scope of the Problem



Average life expectancy is **two to five years** from diagnosis¹



No known therapies to effectively stop or slow progression



ALS is **always fatal**

The overall objective of the ALSRP is to expedite the pathway from bench science to clinical trials for new therapeutic approaches aimed at controlling or curing ALS.



The ALSRP invests congressional appropriations in distinct stages along the therapeutic development pipeline through stepwise translational award mechanisms.



Like all programs within the CDMRP, the ALSRP funds eligible institutions across the globe. There is no requirement for U.S. citizenship to serve as a principal investigator.



The ALSRP funds industry partners and non-profit organizations, as well as more traditional academic research institutions.



¹ cdc.gov

For more information, visit: cdmrp.health.mil/alsrp






ALSRP Award Mechanisms Build A Therapeutic Pipeline




Therapeutic Idea Award \$600,000 / 3 years

- Supports highly innovative, hypothesis-driven preclinical therapeutic development in ALS.
- Proof-of-concept drug discovery.
- Preliminary data are not required.



Therapeutic Development Award \$1,500,000 / 3 years

- Investigational New Drug (IND)-enabling.
- Preliminary data are required, including therapeutic efficacy in at least one ALS-relevant model system.



Pilot Clinical Trial Award \$2,000,000/4 years

- Early phase intervention trials, must include biomarker data.
- Preliminary data are required.
- Inform and de-risk more advanced future trials for the treatment or management of ALS.


New for FY24! Applications must address one focus area:

- Biomarker-Driven Interventions: Disease-modifying interventions, with mechanism-specific predictive, efficacy, and/or pharmacodynamic biomarkers.
- Clinical Care: Improving aspects of clinical care and symptom management for Amyotrophic Lateral Sclerosis.



Clinical Outcomes and Biomarker Award \$750,000 / 3 years

- Development and improvement of clinical biomarkers to enrich clinical trials.
- Biomarker analysis can be therapeutic- or ALS subtype-specific, does not have to broadly apply to all patients.



Deadlines

18 June 2024
Letters of Intent
due 5:00pm EDT*

10 July 2024
Full applications
due 11:59PM EDT

September 2024
Peer Review

November 2024
Programmatic Review

December 2024
Anticipated
Notification

*No invitation will be issued following LOIs. Any applicant who submits an LOI is eligible to submit a full application.

Supporting Community Engagement

Inclusion of community collaboration is a required element for ALSRP-funded clinical research studies that are prospectively enrolling participants. Community collaboration is characterized by equitable partnership between the researcher and community members and representatives. This can be accomplished by a variety of different ways, and the ALSRP encourages all investigators to consider collaboration with the communities they serve.



Sign up for our newsletters: <https://ebrap.org/eBRAP/programSubscription/Subscribe.htm>

FY24 Programmatic Panel - <https://cdmrp.health.mil/alsrp/panels/panels24>

Award Search: <https://cdmrp.health.mil/search.aspx>

For more information, visit: cdmrp.health.mil/alsrp